Search
Azficel-T
go.drugbank.com/drugs/DB11051ApprovedWithdrawnAzficel-T is an autologous cellular product composed of fibroblasts indicated for improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. Dermal fibroblasts are collected from the post-auricular biopsy tis...
CCX915
go.drugbank.com/drugs/DB05159ExperimentalCCX915 is developed by ChemoCentryx which targets the chemokine receptor CCR2 and is in phase 1 of clinical trial for the treatment of Multiple Sclerosis and Neurologic Disorders.
Abemaciclib
go.drugbank.com/drugs/DB12001ApprovedInvestigationalOn September 28, 2017, FDA granted approval of abemaciclib treatment under the market name Verzenio for the treatment of HR-positive and HER2-negative advanced or metastatic breast cancer that has progressed
Rozanolixizumab
go.drugbank.com/drugs/DB14919ApprovedInvestigationalRozanolixizumab-noli is available under the brand name RYSTIGGO and was developed by UCB. … [L47122] It was granted orphan drug designation by the FDA in 2019, by the European Medicines Agency (EMA) in April 2020, and by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA) in November
Potassium cation
go.drugbank.com/drugs/DB01345ApprovedThe balance between potassium and sodium is maintained by ion pumps in the cell membrane. … The cell membrane potential created by potassium and sodium ions allows the cell generate an action potential—a "spike" of electrical discharge.
Tositumomab
go.drugbank.com/drugs/DB00081ApprovedWithdrawnMurine IgG2a lambda monoclonal antibody against CD20 antigen (2 heavy chains of 451 residues, 2 lambda chains of 220 residues). It is produced in an antibiotic-free culture of mammalian cells. It can be covalently linked to Iodine 131 (a...
Aceprometazine
go.drugbank.com/drugs/DB01615ExperimentalAlthough not widely prescribed, it is used in combination with meprobamate for the treatment of sleep disorders in France under the trade name Mepronizine.
Guselkumab
go.drugbank.com/drugs/DB11834ApprovedInvestigationalDeveloped by Janssen, the subcutenous injection form of guselkumab was approved in July 2017 under the market name Tremfya for the treatment of adult patients with moderate-to-severe plaque psoriasis.
Elvitegravir
go.drugbank.com/drugs/DB09101ApprovedInvestigationalElvitegravir was first licensed from Japan Tobacco in 2008 and developed by Gilead Sciences. It was FDA approved on August 27, 2012.
CYNK-001
go.drugbank.com/drugs/DB15722InvestigationalCYNK-001 is a novel allogenic off-the-shelf natural killer (NK) cell therapy originating from human placental CD34+ hematopoietic stem cells and enriched with CD56+/CD3-.